Columbia Asset Management Sells 49,000 Shares of Johnson & Johnson $JNJ

Key Points

• Columbia Asset Management reduced its stake in Johnson & Johnson by 46.9%, selling 49,000 shares during the 2nd quarter, leaving it with a total of 55,430 shares.
• Multiple analysts have raised their price targets for Johnson & Johnson, with JPMorgan Chase setting a new target of $200.00, reflecting a positive outlook on the stock.
• Johnson & Johnson recently declared a quarterly dividend of $1.30 per share, yielding 2.8% at the current price, with a dividend payout ratio of 55.61%.

Columbia Asset Management decreased its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 46.9% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 55,430 shares of the company's stock after selling 49,000 shares during the period. Johnson & Johnson comprises 1.7% of Columbia Asset Management's portfolio, making the stock its 12th biggest position. Columbia Asset Management's holdings in Johnson & Johnson were worth $8,467,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of JNJ. Highline Wealth Partners LLC boosted its holdings in shares of Johnson & Johnson by 51.8% in the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after buying an additional 86 shares during the last quarter. Stone House Investment Management LLC acquired a new stake in shares of Johnson & Johnson in the 1st quarter valued at approximately $47,000. 1248 Management LLC acquired a new stake in shares of Johnson & Johnson in the 1st quarter valued at approximately $48,000. von Borstel & Associates Inc. acquired a new stake in shares of Johnson & Johnson in the 1st quarter valued at approximately $49,000. Finally, Harvest Fund Management Co. Ltd acquired a new stake in shares of Johnson & Johnson in the 1st quarter valued at approximately $52,000. Institutional investors own 69.55% of the company's stock.

Analysts Set New Price Targets

Several research firms have recently commented on JNJ. The Goldman Sachs Group increased their price objective on Johnson & Johnson from $185.00 to $186.00 and gave the company a "buy" rating in a report on Friday, September 19th. Royal Bank Of Canada increased their price target on Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a research note on Thursday, July 17th. JPMorgan Chase & Co. increased their price target on Johnson & Johnson from $185.00 to $200.00 and gave the company a "neutral" rating in a research note on Tuesday, September 16th. Wall Street Zen upgraded Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Saturday, September 13th. Finally, UBS Group increased their price target on Johnson & Johnson from $180.00 to $190.00 and gave the company a "buy" rating in a research note on Thursday, July 17th. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and nine have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $181.40.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. This trade represents a 24.08% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.16% of the stock is owned by insiders.

Johnson & Johnson Stock Up 0.3%

JNJ stock opened at $185.99 on Thursday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The stock has a market capitalization of $447.92 billion, a price-to-earnings ratio of 19.89, a PEG ratio of 2.36 and a beta of 0.40. The business's fifty day moving average price is $175.45 and its two-hundred day moving average price is $162.51. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $186.56.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.09. The firm had revenue of $23.74 billion for the quarter, compared to analysts' expectations of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The company's quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter last year, the business earned $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, equities analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were given a dividend of $1.30 per share. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.8%. Johnson & Johnson's dividend payout ratio (DPR) is presently 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.